mTOR pathway
Selected indexed studies
- Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer. (Semin Cancer Biol, 2022) [PMID:34175443]
- Drugging the PI3K/AKT/mTOR Pathway in ER+ Breast Cancer. (Int J Mol Sci, 2023) [PMID:36901954]
- The PI3K/AKT/mTOR interactive pathway. (Mol Biosyst, 2015) [PMID:25924008]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer. (2022) pubmed
- Drugging the PI3K/AKT/mTOR Pathway in ER+ Breast Cancer. (2023) pubmed
- The PI3K/AKT/mTOR interactive pathway. (2015) pubmed
- Baicalein induces apoptosis by inhibiting the glutamine-mTOR metabolic pathway in lung cancer. (2025) pubmed
- mTOR at the nexus of nutrition, growth, ageing and disease. (2020) pubmed
- The mTOR pathway in the control of protein synthesis. (2006) pubmed
- Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: A novel therapeutic strategy. (2022) pubmed
- mTOR pathway: A potential therapeutic target for spinal cord injury. (2022) pubmed
- Impairment of insulin signaling pathway PI3K/Akt/mTOR and insulin resistance induced AGEs on diabetes mellitus and neurodegenerative diseases: a perspective review. (2023) pubmed
- PI3K/Akt/mTOR pathway: a potential target for anti-SARS-CoV-2 therapy. (2022) pubmed